Boucher, Kenneth M.

Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework

Tavtigian, S. V., Greenblatt, M. S., Harrison, S. M., Nussbaum, R. L., Prabhu, S. A., Boucher, K. M., & Biesecker, L. G. (2018) · Genetics in Medicine

Genomics and Rare DiseasesBRCA gene mutations in cancer

Cited by 590

Microsatellites as EWS/FLI response elements in Ewing's sarcoma

Gangwal, K., Sankar, S., Hollenhorst, P. C., Kinsey, M., Haroldsen, S. C., Shah, A. A., Boucher, K. M., Watkins, W. S., Jorde, L. B., Graves, B. J., et al. (2008) · Proceedings of the National Academy of Sciences

Sarcoma Diagnosis and TreatmentGenomics and Chromatin Dynamics

Cited by 297

The p16INK4A tumor suppressor regulates cellular oxidative stress

Jenkins, N. C., Liu, T., Cassidy, P., Leachman, S. A., Boucher, K. M., Goodson, A. G., Samadashwily, G., & Grossman, D. (2011) · Oncogene

Redox biology and oxidative stressCancer-related Molecular Pathways

Cited by 138

Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong

Campo, R. A., Agarwal, N., LaStayo, P. C., O’Connor, K., Pappas, L., Boucher, K. M., Gardner, J., Smith, S., Light, K. C., & Kinney, A. Y. (2014) · Journal of Cancer Survivorship

Cancer survivorship and careComplementary and Alternative Medicine Studies

Cited by 102

GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance

Luo, W., Gangwal, K., Sankar, S., Boucher, K. M., Thomas, D., & Lessnick, S. L. (2009) · Oncogene

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 93

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer

Cowman, S. J., Fuja, D. G., Liu, X.-D., Tidwell, R. S. S., Kandula, N., Sirohi, D., Agarwal, A. M., Emerson, L. L., Tripp, S. R., Mohlman, J. S., et al. (2020) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 76

Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Swami, U., Maughan, B. L., Boucher, K. M., Nordblad, B., Lloyd, J., Batten, J., Phunrab, T. K., Quertinmont, J., Kohli, M., Gupta, S., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations

Cited by 9